Does the media prefer MRNA or APGE?

In the previous week, Moderna had 6 more articles in the media than Apogee Therapeutics. MarketBeat recorded 12 mentions for Moderna and 6 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.14 beat Moderna's score of 0.18 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Apogee Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ROIV or APGE?

In the previous week, Roivant Sciences had 3 more articles in the media than Apogee Therapeutics. MarketBeat recorded 9 mentions for Roivant Sciences and 6 mentions for Apogee Therapeutics. Roivant Sciences' average media sentiment score of 1.31 beat Apogee Therapeutics' score of 1.14 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor APGE or INSM?

In the previous week, Insmed had 16 more articles in the media than Apogee Therapeutics. MarketBeat recorded 22 mentions for Insmed and 6 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.14 beat Insmed's score of 0.93 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 13 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer APGE or BNTX?

In the previous week, BioNTech had 3 more articles in the media than Apogee Therapeutics. MarketBeat recorded 9 mentions for BioNTech and 6 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.14 beat BioNTech's score of 0.63 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Apogee Therapeutics (APGE) Competitors

$134.23 +0.08 (+0.06%)

As of 10:38 AM Eastern

Compare

APGE vs. MRNA, ROIV, INSM, BNTX, and VTRS

Should you buy Apogee Therapeutics stock or one of its competitors? MarketBeat compares Apogee Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Apogee Therapeutics include Moderna (MRNA), Roivant Sciences (ROIV), Insmed (INSM), BioNTech (BNTX), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does Apogee Therapeutics compare to Moderna?

Moderna (NASDAQ:MRNA) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

75.3% of Moderna shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Moderna presently has a consensus price target of $40.00, suggesting a potential downside of 33.31%. Apogee Therapeutics has a consensus price target of $121.25, suggesting a potential downside of 9.66%. Given Apogee Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Apogee Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24

Apogee Therapeutics has lower revenue, but higher earnings than Moderna. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	12.24	-$2.82B	-$8.15	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

Moderna has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Apogee Therapeutics has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Apogee Therapeutics	N/A	-32.64%	-31.25%

In the previous week, Moderna had 6 more articles in the media than Apogee Therapeutics. MarketBeat recorded 12 mentions for Moderna and 6 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.14 beat Moderna's score of 0.18 indicating that Apogee Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Apogee Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Apogee Therapeutics beats Moderna on 10 of the 16 factors compared between the two stocks.

How does Apogee Therapeutics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Apogee Therapeutics has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Apogee Therapeutics	N/A	-32.64%	-31.25%

In the previous week, Roivant Sciences had 3 more articles in the media than Apogee Therapeutics. MarketBeat recorded 9 mentions for Roivant Sciences and 6 mentions for Apogee Therapeutics. Roivant Sciences' average media sentiment score of 1.31 beat Apogee Therapeutics' score of 1.14 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Roivant Sciences has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

Roivant Sciences presently has a consensus price target of $33.59, indicating a potential downside of 3.48%. Apogee Therapeutics has a consensus price target of $121.25, indicating a potential downside of 9.66%. Given Roivant Sciences' stronger consensus rating and higher probable upside, research analysts clearly believe Roivant Sciences is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24

Apogee Therapeutics has lower revenue, but higher earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,030.60	-$299.77M	-$0.60	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Roivant Sciences beats Apogee Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Apogee Therapeutics compare to Insmed?

Apogee Therapeutics (NASDAQ:APGE) and Insmed (NASDAQ:INSM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

In the previous week, Insmed had 16 more articles in the media than Apogee Therapeutics. MarketBeat recorded 22 mentions for Insmed and 6 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.14 beat Insmed's score of 0.93 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	13 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Apogee Therapeutics has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Apogee Therapeutics' return on equity of -32.64% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
Insmed	-144.44%	-130.11%	-51.57%

Apogee Therapeutics presently has a consensus target price of $121.25, suggesting a potential downside of 9.66%. Insmed has a consensus target price of $209.13, suggesting a potential upside of 93.19%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24
Insmed	1 Sell rating(s)	0 Hold rating(s)	24 Buy rating(s)	1 Strong Buy rating(s)	2.96

Apogee Therapeutics has higher earnings, but lower revenue than Insmed. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
Insmed	$606.42M	38.69	-$1.28B	-$5.75	N/A

Apogee Therapeutics has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Insmed has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

79.0% of Apogee Therapeutics shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Apogee Therapeutics beats Insmed on 8 of the 15 factors compared between the two stocks.

How does Apogee Therapeutics compare to BioNTech?

Apogee Therapeutics (NASDAQ:APGE) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Apogee Therapeutics has higher earnings, but lower revenue than BioNTech. Apogee Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
BioNTech	$3.25B	7.22	-$1.29B	-$5.88	N/A

Apogee Therapeutics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market.

Apogee Therapeutics has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
BioNTech	-44.39%	-5.30%	-4.62%

In the previous week, BioNTech had 3 more articles in the media than Apogee Therapeutics. MarketBeat recorded 9 mentions for BioNTech and 6 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.14 beat BioNTech's score of 0.63 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Apogee Therapeutics currently has a consensus price target of $121.25, suggesting a potential downside of 9.66%. BioNTech has a consensus price target of $129.13, suggesting a potential upside of 39.30%. Given BioNTech's stronger consensus rating and higher possible upside, analysts plainly believe BioNTech is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

Summary

BioNTech beats Apogee Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Apogee Therapeutics compare to Viatris?

Viatris (NASDAQ:VTRS) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

79.9% of Viatris shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Viatris presently has a consensus price target of $17.50, suggesting a potential upside of 1.63%. Apogee Therapeutics has a consensus price target of $121.25, suggesting a potential downside of 9.66%. Given Viatris' stronger consensus rating and higher possible upside, analysts plainly believe Viatris is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.24

Apogee Therapeutics has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Apogee Therapeutics	N/A	-32.64%	-31.25%

Viatris has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

In the previous week, Apogee Therapeutics had 6 more articles in the media than Viatris. MarketBeat recorded 6 mentions for Apogee Therapeutics and 0 mentions for Viatris. Apogee Therapeutics' average media sentiment score of 1.14 beat Viatris' score of 0.00 indicating that Apogee Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Viatris	Neutral
Apogee Therapeutics	Positive

Apogee Therapeutics has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.40	-$3.51B	-$0.26	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

Summary

Viatris beats Apogee Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Apogee Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APGE vs. The Competition

Export

Metric	Apogee Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.31B	$3.64B	$6.80B	$12.37B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-31.00	20.71	27.09	24.07
Price / Sales	N/A	302.58	520.26	91.86
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	10.15	7.99	10.64	6.20
Net Income	-$255.84M	$23.81M	$3.60B	$331.63M
7 Day Performance	0.20%	-1.92%	-1.41%	-1.54%
1 Month Performance	48.51%	1.88%	0.97%	-1.17%
1 Year Performance	243.19%	43.58%	24.23%	17.81%

Apogee Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APGE Apogee Therapeutics	1.9107 of 5 stars	$134.22 +0.1%	$121.25 -9.7%	+241.3%	$8.31B	N/A	N/A	91	Positive News
MRNA Moderna	1.7362 of 5 stars	$66.37 -0.9%	$38.27 -42.3%	+90.3%	$26.37B	$1.94B	N/A	4,700	Analyst Forecast Gap Down
ROIV Roivant Sciences	1.8577 of 5 stars	$34.88 +1.1%	$33.59 -3.7%	+197.6%	$25.06B	$8.26M	N/A	860
INSM Insmed	4.0892 of 5 stars	$108.21 -0.9%	$211.00 +95.0%	+4.3%	$23.30B	$606.42M	N/A	1,664	News Coverage Analyst Forecast
BNTX BioNTech	4.4345 of 5 stars	$90.00 -0.1%	$129.13 +43.5%	-16.2%	$22.80B	$3.25B	N/A	7,807	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APGE) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Apogee Therapeutics (APGE) Competitors

APGE vs. MRNA, ROIV, INSM, BNTX, and VTRS

How does Apogee Therapeutics compare to Moderna?

Summary

How does Apogee Therapeutics compare to Roivant Sciences?

Summary

How does Apogee Therapeutics compare to Insmed?

Summary

How does Apogee Therapeutics compare to BioNTech?

Summary

How does Apogee Therapeutics compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APGE vs. The Competition

Apogee Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Apogee Therapeutics (APGE) Competitors

APGE vs. MRNA, ROIV, INSM, BNTX, and VTRS

How does Apogee Therapeutics compare to Moderna?

Do insiders and institutionals have more ownership in MRNA or APGE?

Do analysts rate MRNA or APGE?

Which has stronger earnings and valuation, MRNA or APGE?

Which has more risk and volatility, MRNA or APGE?

Is MRNA or APGE more profitable?

Does the media prefer MRNA or APGE?

Summary

How does Apogee Therapeutics compare to Roivant Sciences?

Is ROIV or APGE more profitable?

Does the media prefer ROIV or APGE?

Which has more volatility & risk, ROIV or APGE?

Do analysts prefer ROIV or APGE?

Which has preferable valuation & earnings, ROIV or APGE?

Do institutionals & insiders believe in ROIV or APGE?

Summary

How does Apogee Therapeutics compare to Insmed?

Does the media favor APGE or INSM?

Is APGE or INSM more profitable?

Do analysts rate APGE or INSM?

Which has higher valuation and earnings, APGE or INSM?

Which has more risk and volatility, APGE or INSM?

Do insiders and institutionals have more ownership in APGE or INSM?

Summary

How does Apogee Therapeutics compare to BioNTech?

Which has preferable valuation and earnings, APGE or BNTX?

Which has more risk & volatility, APGE or BNTX?

Is APGE or BNTX more profitable?

Does the media prefer APGE or BNTX?

Do institutionals and insiders have more ownership in APGE or BNTX?

Do analysts recommend APGE or BNTX?

Summary

How does Apogee Therapeutics compare to Viatris?

Do institutionals and insiders have more ownership in VTRS or APGE?

Do analysts prefer VTRS or APGE?

Is VTRS or APGE more profitable?

Which has more risk & volatility, VTRS or APGE?

Does the media refer more to VTRS or APGE?

Which has higher valuation & earnings, VTRS or APGE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APGE vs. The Competition

Apogee Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools